KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Inventory (2016 - 2025)

Sarepta Therapeutics has reported Inventory over the past 10 years, most recently at $914.7 million for Q4 2025.

  • Quarterly results put Inventory at $914.7 million for Q4 2025, up 21.97% from a year ago — trailing twelve months through Dec 2025 was $914.7 million (up 21.97% YoY), and the annual figure for FY2025 was $914.7 million, up 21.97%.
  • Inventory for Q4 2025 was $914.7 million at Sarepta Therapeutics, down from $1.1 billion in the prior quarter.
  • Over the last five years, Inventory for SRPT hit a ceiling of $1.1 billion in Q3 2025 and a floor of $186.2 million in Q4 2021.
  • Median Inventory over the past 5 years was $278.6 million (2021), compared with a mean of $445.8 million.
  • Biggest five-year swings in Inventory: fell 23.32% in 2022 and later skyrocketed 152.04% in 2025.
  • Sarepta Therapeutics' Inventory stood at $186.2 million in 2021, then grew by 9.54% to $204.0 million in 2022, then soared by 58.29% to $322.9 million in 2023, then surged by 132.29% to $750.0 million in 2024, then rose by 21.97% to $914.7 million in 2025.
  • The last three reported values for Inventory were $914.7 million (Q4 2025), $1.1 billion (Q3 2025), and $994.0 million (Q2 2025) per Business Quant data.